CCD Partners

🔍 What are the key points to consider for a successful acquisition?    A successful acquisition hinges on a precise understanding of the key value drivers and synergies – in other words, why the prospective buyer would be a good new home for the business.      Key considerations include:    • Identifying the core value drivers – Define the strategic goals motivating the acquisition, whether this is revenue growth, access to new markets, or operational efficiencies.  • Analysing synergies – Quantify sources of value creation, such as cross-selling or shared capabilities  • Executing with precision – Ensure a strong understanding of the transaction process, conduct in-depth due diligence, and develop an integration plan for the first 6-12 months.     These are just a few of the factors which underpin a successful transaction. For more insights, get in touch with Basil Saeed, our Associate Partner.  🌐 📈    #StrategicGrowth #GrowthStrategies #MergersandAcquisitions

We tracked 12 M&A deals in the fine and specialty chemicals markets this week 📈     Chemical highlights feature our top-five recent global M&A and senior people moves.     Sign up here to receive the full list  ➡️ https://lnkd.in/eqkaV4zS      1. Merck has acquired Modifi Biosciences, a company specialising in direct DNA modification-enabled cancer therapeutics, for $30 million. This acquisition, which includes an additional potential $1.3 billion in milestone payments, strengthens Merck's position in oncology and leverages Modifi’s pioneering science to drive future clinical advancements for glioblastoma and other tumour treatments.     2. Chevron Phillips Chemical Company and LyondellBasell, alongside other investors, have taken an equity stake in Alterra, a company advancing recycling technology for plastic circularity. This funding, led by Infinity Recycling, supports Alterra's mission to commercialise its technology globally, converting waste plastic into valuable raw materials to foster a sustainable, circular economy.    3. Cold Chain Technologies (CCT) has acquired Tower Cold Chain, headquartered in the UK, a provider of passive reusable cold chain solutions. This acquisition, CCT's fourth since 2019, aligns with its expansion strategy and solidifies its leadership in temperature-sensitive logistics.   4. Alphina Therapeutics has appointed Nick Galli as CEO and board member, leveraging his 20 years of experience in biotech strategy, business development, and capital raising. Galli’s expertise, alongside his prior roles at Interline Therapeutics and CytomX Therapeutics, positions him well to advance Alphina's NAMPT tumour inhibitor program, targeting clinical entry within 18 months.    5. Parexel, a global clinical research organization, has named Keri P. Mattox as its chief business officer, tasked with leading the company’s business operations and growth strategy. Mattox brings over 25 years of healthcare industry experience, including roles in corporate strategy and ESG at Zimmer Biomet, that will position her to excel in her new position.    #MergersandAcquisitions #CorporateDevelopments #ChemicalIndustry 

Our deal of the month for October highlights ADNOC Germany AG's takeover offer for Covestro.    🔹 Summary: ADNOC Group Germany AG has offered €62.00 per Covestro share, representing a 54% premium on the share price. The offer will generate €1.17 billion in proceeds through a capital increase of 18.9 million new shares.    🔹 Rationale: This transaction would strengthen Covestro’s financial position and supports its sustainable future growth strategy, It would be ADNOC’s biggest ever acquisition and would enhance Covestro’s capacity to execute its green transformation. 📊    🔹 Market Impact: Covestro shares jumped 3.7%, reaching a three-year high following the announcement.     Read more about the deal here: https://lnkd.in/ejvDmEzT    #DealoftheMonth #ADNOC #Covestro #StrategicGrowth #MergersandAcquisitions  

Why do we post the top M&A corporate developments from the chemicals and life sciences sectors each week?    🌐 We are committed to sharing key deals and people moves from the chemicals and life sciences landscape  ⚙️ To broaden our industry network and to share the most relevant opportunities     We are always monitoring key companies throughout the chemical industry globally. We also confirm these updates through our network of senior advisors, ensuring that the most important and relevant deals are shared with you in our weekly tracker.    Sign up for free here: https://lnkd.in/ewC_YhmR    For any questions, feel free to contact Julia Monahan.

CCD Partners Wrapped: Key Stats 📊   Over the past six months, CCD Partners has been actively engaged in the specialty chemicals and pharma services markets: 🎯 2,000+ companies connected with, expanding our network across the space.  🤝 150+ in-person and virtual meetings held.  🚀 60+ companies seeking corporate developments for strategic growth.    Our core team and our advisory network have been instrumental over the past six months in helping us achieve these milestones. We look forward to continuing this momentum and providing more updates into 2025.     #StrategicConsulting #StrategicGrowth #CCDPartners

2024 Outlook Across US Chemical Sectors 📊🌱    The American Chemistry Council's mid-year 2024 report highlighted notable trends across specialties, basic chemicals, agricultural chemicals, and consumer products. U.S. chemical production is set to rebound by the end of 2024, with growth across key sectors.    Noteworthy projections from the report:  • Basic chemical output will rise 2.5%, driven by gains in petrochemicals, inorganic chemicals, and plastic resins.  • Plastic resins are expected to grow 2.9%, largely supported by stronger exports.  • Specialty chemicals will only see a 0.4% increase, reflecting slower recovery in end-use markets.    Globally, chemical production is forecast to increase by 3.4% by the end of 2024, with the largest gains in Asia/Pacific and Europe. 🌍    #Chemicals #IndustryForecast #ACC 

We tracked 16 M&A deals in the fine and specialty chemicals markets this week 📈     Chemical highlights feature our top-five recent global M&A and senior people moves.     Sign up here to receive the full list  ➡️ https://lnkd.in/eqkaV4zS      1. Honeywell plans to spin off its advanced materials business into a standalone, publicly traded company by early 2026, with anticipated revenue of $3.8 billion and an EBITDA margin exceeding 25%. This move aims to provide greater financial flexibility and a strategic focus on innovation, sustainability, and long-term growth in specialty chemicals.     2. Lundbeck has acquired Longboard Pharmaceuticals in a strategic $2.6bn deal, significantly enhancing its neuroscience pipeline. This acquisition adds late-stage development assets for developmental and epileptic encephalopathies, areas of high unmet medical need.     3. Olivier Falut has been appointed chief financial officer of EUROAPI, effective 17 October 2024, succeeding Evelyne Nguyen. With experience as CFO of Sodiaal, Limagrain, and Segula Technologies, he brings extensive expertise in financial leadership across multiple industrial sectors.     4. LyondellBasell (LYB) has completed its acquisition of APK AG, further developing APK's solvent-based recycling technology for low-density polyethylene. This acquisition supports LYB's goal to expand its circulen portfolio, addressing customer demands for sustainable packaging solutions through advanced recycling technologies.    5. PPG, a leader in paints, coatings, and specialty materials, has announced the sale of its architectural coatings business in the U.S. and Canada to American Industrial Partners (AIP) for $550 million. This transaction, is part of PPG’s strategy to optimise its portfolio, following a comprehensive cost reduction program that targets pre-tax savings of $175 million annually.    #MergersandAcquisitions #CorporateDevelopments #ChemicalIndustry 

📢 🔬 Incoming Chemical Distribution Disruptor Watchlist...     Our research team has been interviewing disruptors for the latest edition of our Chemical Distribution Disruptor Watchlist! 🧪     This report will highlight companies driving innovation and breakthrough technologies in the chemical distribution sector.    Why do we create Disruptor Watchlists?  • To feature emerging companies making significant strides in chemical distribution  • To widen our network and provide exposure for these innovative and independent companies     The 2024/25 Chemical Distribution Watchlist will be a free report, focusing on up-and-coming companies with HQs in North America or Europe.     We are looking forward to sharing the insights from the report and our interviews with owners and managers of these disruptive businesses.    #ChemicalDistribution #Watchlist #ChemicalInnovation #ChemicalIndustry 

Did you know that CCD Partners has a senior advisor that specialises in environmental technologies? 🌱 ⚙️       Dr Michelle Lynch FRSC brings over 27 years of experience in the chemical sector, with 14 years spent at Johnson Matthey and 13 years consulting for start-ups, SMEs, and multinational blue-chip companies.      Her clients span across Europe, North America, and Asia, and she has built a solid reputation for her extensive knowledge in CO2 utilisation, catalysis, rechargeable battery materials, critical metals, bio-renewables and circular economy.     #SeniorAdvisor #ChemicalIndustry #EnergyTransition

💡 Big pharma and academic institutions join forces amid economic slump    As drug companies navigate financial pressures, partnerships with universities have become key for early-stage research. The number of apprentices, undergraduates, PhD students, and postdoctoral researchers in the UK pharmaceutical industry has reached an all-time high.     Collaborations such as these bring about reduced risk for pharma businesses, and are key for fuelling growth and advancing knowledge in the drug discovery space.     Overview of key stats:  • Research partnerships between companies and academic institutions have risen globally and are at an all-time high in the UK.  • Pharma firms spent $83 billion on R&D in 2019, a tenfold increase from the 1980s.     🔬 Read more about this trend in the pharmaceutical industry here: https://lnkd.in/e422Ytj2    #PharmaceuticalIndustry #ResearchInnovation